WEBINAR ON DEMAND
Duration: 1 hour
HPV plays a key role in oropharyngeal cancer, causing an estimated 70% of the 20,839 cases diagnosed in the U.S. each year. It’s also a positive prognostic indicator, as patients with HPV+ OPSCC tend to have less aggressive forms of the disease.
However, pathologists have traditionally not had access to good prognostic biomarkers for HPV driven OPSCC. As a result, sponsors and CROs have had limited opportunities to leverage biomarker testing for candidate selection, measuring treatment response and detecting recurrence among HPV+ OPSCC patients.
cfHPV-DNA has recently emerged as a novel prognostic biomarker for HPV+ OPSCC, with the potential to transform clinical research and therapeutic development. In this webinar, you’ll learn: